Abstract
Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).
Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.
Current Pharmaceutical Design
Title:Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation
Volume: 22 Issue: 16
Author(s): Sara Mongiorgi, Matilde Y. Follo, Yong Ryoul Yang, Stefano Ratti, Lucia Manzoli, James A. McCubrey, Anna Maria Billi, Pann-Ghill Suh and Lucio Cocco
Affiliation:
Keywords: PI-PLCbeta1, Nucleus, Cell Cycle, Differentiation, Hematopoiesis, MDS.
Abstract: Nuclear phosphoinositide-phospholipase C (PI-PLC) beta1 plays a crucial role in the molecular steps that regulate cell proliferation and differentiation in several experimental models, such as myoblasts and hematopoietic cells, via interaction with other important molecular players. Indeed, PI-PLCbeta1 and its related molecules are definitely involved in hematopoiesis, and particularly in drug-induced myeloid or erythroid differentiation. Here, we review the role of nuclear PI-PLCbeta1 signalling in normal hematopoiesis, in pathogenesis and in drug-related induction of hematopoietic differentiation, with particular reference to the current therapy of Myelodysplastic Syndromes (MDS).
Export Options
About this article
Cite this article as:
Mongiorgi Sara, Y. Follo Matilde, Ryoul Yang Yong, Ratti Stefano, Manzoli Lucia, A. McCubrey James, Maria Billi Anna, Suh Pann-Ghill and Cocco Lucio, Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160226132338
DOI https://dx.doi.org/10.2174/1381612822666160226132338 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of Molecularly Targeted Therapies Upon the Understanding of Leukemogenesis and the Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia
Current Stem Cell Research & Therapy Mechanistic Insights into the Antileukemic Activity of Hyperforin
Current Cancer Drug Targets Effects of Tyrosine Kinase Inhibitors on Growth and Bone Metabolism in Children with Haematologic Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Short Antimicrobial Peptides and Peptide Scaffolds as Promising Antibacterial Agents
Current Topics in Medicinal Chemistry Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphom a Molecular Subtypes: A Cell of Origin-Driven Review
Current Cancer Drug Targets Development of Agents that Modulate Protein-Protein Interactions in Membranes
Current Pharmaceutical Design The Leukocyte Common Antigen-Related Protein LAR: Candidate PTP for Inhibitory Targeting
Current Topics in Medicinal Chemistry Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Current Management of Fetal and Neonatal Renal Tumors
Current Pediatric Reviews Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Anti-Angiogenesis Activities of Dietary Constituents and Health Foods with Potential Anti-Hepatocellular Carcinoma Activity
Recent Patents on Biomarkers Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
Current Pharmaceutical Design